Application of immunosuppressant in IgG4-related autoimmune pancreatitis / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 1614-1618, 2018.
Article
in Zh
| WPRIM
| ID: wpr-779017
Responsible library:
WPRO
ABSTRACT
At present, glucocorticoids are the first-line drugs for the treatment of type 1 autoimmune pancreatitis, which is also known as IgG4-related autoimmune pancreatitis. Combined treatment with immunosuppressant and glucocorticoids helps to reduce the dose of glucocorticoids and maintain long-term remission. There are no high-quality evidence-based prospective studies of immunosuppressant in the treatment of IgG4-related disease. No uniform standards have been developed in China and the rest of the world, and the treatment of this disease mainly draws experience from other autoimmune diseases. This article introduces the application of conventional drugs (including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, and cyclosporine) and biological therapy (for example, rituximab targeting B lymphocytes) in the treatment of autoimmune pancreatitis.
Full text:
1
Index:
WPRIM
Type of study:
Guideline
/
Observational_studies
Language:
Zh
Journal:
Journal of Clinical Hepatology
Year:
2018
Type:
Article